Literature DB >> 25068424

Incidence and risk factors for moderate-to-severe veno-occlusive disease of the liver after allogeneic stem cell transplantation using a reduced intensity conditioning regimen.

P D Tsirigotis1, I B Resnick1, B Avni1, S Grisariu1, P Stepensky1, R Or1, M Y Shapira1.   

Abstract

The incidence and outcome of moderate-to-severe veno-occlusive (VOD) disease was analyzed in 271 consecutive patients with hematological malignancies who underwent allogeneic SCT (allo-SCT) using the same reduced intensity regimen (RIC). RIC consisted of fludarabine, BU and antithymocyte globulin (ATG). Twenty-four out of 271 patients (8.8%) developed VOD, which was severe in only 4 (1.4%) out of 24 cases. All four patients with severe VOD finally succumbed to their disease. In multivariate analysis, i.v. administration of BU was associated with significant reduced incidence of VOD as compared with per os administration. In conclusion, VOD remains a serious complication of allo-SCT using RIC regimens containing BU. Although the incidence of severe VOD is very low, the overall mortality rate in the group of patients with severe VOD remains extremely high and therefore novel treatment approaches are needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25068424     DOI: 10.1038/bmt.2014.168

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  14 in total

1.  The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.

Authors:  Enric Carreras; Marina Díaz-Beyá; Laura Rosiñol; Carmen Martínez; Francesc Fernández-Avilés; Montserrat Rovira
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-25       Impact factor: 5.742

Review 2.  The role of the endothelium in the short-term complications of hematopoietic SCT.

Authors:  E Carreras; M Diaz-Ricart
Journal:  Bone Marrow Transplant       Date:  2011-04-04       Impact factor: 5.483

3.  Venoocclusive disease of the liver following bone marrow transplantation.

Authors:  R J Jones; K S Lee; W E Beschorner; V G Vogel; L B Grochow; H G Braine; G B Vogelsang; L L Sensenbrenner; G W Santos; R Saral
Journal:  Transplantation       Date:  1987-12       Impact factor: 4.939

Review 4.  Veno-occlusive disease of the liver after hemopoietic cell transplantation.

Authors:  E Carreras
Journal:  Eur J Haematol       Date:  2000-05       Impact factor: 2.997

Review 5.  Veno-occlusive disease: cytokines, genetics, and haemostasis.

Authors:  Jason A Coppell; Simon A Brown; David J Perry
Journal:  Blood Rev       Date:  2003-06       Impact factor: 8.250

6.  The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin.

Authors:  P Tsirigotis; M Y Shapira; R Or; M Bitan; S Samuel; B Gesundheit; A Ackerstein; A Abdul-Hai; S Slavin; I B Resnick
Journal:  Bone Marrow Transplant       Date:  2009-11-30       Impact factor: 5.483

7.  Investigation of the freely available easy-to-use software 'EZR' for medical statistics.

Authors:  Y Kanda
Journal:  Bone Marrow Transplant       Date:  2012-12-03       Impact factor: 5.483

8.  Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors.

Authors:  G B McDonald; P Sharma; D E Matthews; H M Shulman; E D Thomas
Journal:  Hepatology       Date:  1984 Jan-Feb       Impact factor: 17.425

9.  Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.

Authors:  G B McDonald; M S Hinds; L D Fisher; H G Schoch; J L Wolford; M Banaji; B J Hardin; H M Shulman; R A Clift
Journal:  Ann Intern Med       Date:  1993-02-15       Impact factor: 25.391

10.  Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.

Authors:  Paul G Richardson; Carol Murakami; Zhezhen Jin; Diane Warren; Parisa Momtaz; Deborah Hoppensteadt; Anthony D Elias; Joseph H Antin; Robert Soiffer; Thomas Spitzer; David Avigan; Scott I Bearman; Paul L Martin; Joanne Kurtzberg; James Vredenburgh; Allen R Chen; Sally Arai; Georgia Vogelsang; George B McDonald; Eva C Guinan
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

View more
  21 in total

1.  Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.

Authors:  Paul G Richardson; Angela R Smith; Brandon M Triplett; Nancy A Kernan; Stephan A Grupp; Joseph H Antin; Leslie Lehmann; Maja Miloslavsky; Robin Hume; Alison L Hannah; Bijan Nejadnik; Robert J Soiffer
Journal:  Br J Haematol       Date:  2017-04-26       Impact factor: 6.998

2.  Reversible sinusoidal obstruction syndrome associated with tacrolimus following liver transplantation.

Authors:  Tian Shen; Xiao-Wen Feng; Lei Geng; Shu-Sen Zheng
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

Review 3.  Modified diagnostic criteria, grading classification and newly elucidated pathophysiology of hepatic SOS/VOD after haematopoietic cell transplantation.

Authors:  Mitchell S Cairo; Kenneth R Cooke; Hillard M Lazarus; Nelson Chao
Journal:  Br J Haematol       Date:  2020-03-04       Impact factor: 6.998

Review 4.  The use of defibrotide in blood and marrow transplantation.

Authors:  Paul G Richardson; Enric Carreras; Massimo Iacobelli; Bijan Nejadnik
Journal:  Blood Adv       Date:  2018-06-26

5.  Incidence and management of hepatic severe veno-occlusive disease in 273 patients in a single centre with defibrotide.

Authors:  R R Pol; N Russell; E Das-Gupta; L Watson; L Rachael; J Byrne
Journal:  Bone Marrow Transplant       Date:  2016-04-25       Impact factor: 5.483

6.  Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.

Authors:  Nancy A Kernan; Paul G Richardson; Angela R Smith; Brandon M Triplett; Joseph H Antin; Leslie Lehmann; Yoav Messinger; Wei Liang; Robin Hume; William Tappe; Robert J Soiffer; Stephan A Grupp
Journal:  Pediatr Blood Cancer       Date:  2018-06-06       Impact factor: 3.167

7.  Inferior vena cava stenosis-induced sinusoidal obstructive syndrome after living donor liver transplantation.

Authors:  Batsaikhan Bat-Erdene; Sergelen Orgoi; Erdene Sandag; Ulzii-Orshikh Namkhai; Bat-Ireedui Badarch; Batsaikhan Batsuuri
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2016-08-29

8.  Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy.

Authors:  Marie-Luise Hütter-Krönke; Axel Benner; Konstanze Döhner; Jürgen Krauter; Daniela Weber; Margit Moessner; Claus-Henning Köhne; Heinz A Horst; Ingo G H Schmidt-Wolf; Mathias Rummel; Katharina Götze; Elisabeth Koller; Andreas L Petzer; Hans Salwender; Walter Fiedler; Heinz Kirchen; Detlef Haase; Stephan Kremers; Matthias Theobald; Axel C Matzdorff; Arnold Ganser; Hartmut Döhner; Richard F Schlenk
Journal:  Haematologica       Date:  2016-04-01       Impact factor: 9.941

Review 9.  Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.

Authors:  Paul G Richardson; Stephan A Grupp; Antonio Pagliuca; Amrita Krishnan; Vincent T Ho; Selim Corbacioglu
Journal:  Int J Hematol Oncol       Date:  2017-08-11

10.  Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.

Authors:  Paul G Richardson; Marcie L Riches; Nancy A Kernan; Joel A Brochstein; Shin Mineishi; Amanda M Termuhlen; Sally Arai; Stephan A Grupp; Eva C Guinan; Paul L Martin; Gideon Steinbach; Amrita Krishnan; Eneida R Nemecek; Sergio Giralt; Tulio Rodriguez; Reggie Duerst; John Doyle; Joseph H Antin; Angela Smith; Leslie Lehmann; Richard Champlin; Alfred Gillio; Rajinder Bajwa; Ralph B D'Agostino; Joseph Massaro; Diane Warren; Maja Miloslavsky; Robin L Hume; Massimo Iacobelli; Bijan Nejadnik; Alison L Hannah; Robert J Soiffer
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.